Pieris Pharmaceuticals (Pieris Pharmaceuticals) Market Cap : $13.88 Mil (As of May. 14, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pieris Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pieris Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $14.56. Pieris Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 1.24 Mil. Therefore, Pieris Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $18.01 Mil.

Pieris Pharmaceuticals's quarterly market cap increased from Jun. 2023 ($16.36 Mil) to Sep. 2023 ($29.46 Mil) but then declined from Sep. 2023 ($29.46 Mil) to Dec. 2023 ($18.01 Mil).

Pieris Pharmaceuticals's annual market cap declined from Dec. 2021 ($273.00 Mil) to Dec. 2022 ($77.50 Mil) and declined from Dec. 2022 ($77.50 Mil) to Dec. 2023 ($18.01 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pieris Pharmaceuticals's Enterprise Value for Today is $-12.35 Mil.

Pieris Pharmaceuticals Market Cap Historical Data

The historical data trend for Pieris Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals Market Cap Chart

Pieris Pharmaceuticals Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

199.87

140.01

273.00

77.50

18.01

Pieris Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															77.50	72.73	16.36	29.46	18.01

Competitive Comparison of Pieris Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Pieris Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pieris Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's Market Cap falls into.

Pieris Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Pieris Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$14.56	*	1.23669
	=	$18.01

Pieris Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$14.56	*	1.23669
	=	$18.01

Pieris Pharmaceuticals (NAS:PIRS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Pieris Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (NAS:PIRS) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

PI6:Germany

Address

225 Franklin Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.pieris.com

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

Executives

Ann Barbier	director	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Maya R. Said	director	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Matthew L Sherman	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Christopher P Kiritsy	director
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Shane Olwill	officer: Chief Development Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Ahmed Mousa	officer: Chief Business Officer	255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109
Hitto Kaufmann	officer: Chief Scientific Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Thomas Bures	officer: Chief Financial Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Tim Demuth	officer: Chief Medical Officer	C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Aquilo Capital Management, Llc	10 percent owner	ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104